Comments
Marksans Pharma on Thursday informed the exchanges that the US FDA has issued Form 483 with eight observations on conclusion of inspection at its Goa facility. The inspection was held during February 26 to March 6. “None of these observations are considered either critical or repetitive in nature. The company is highly confident of closing these expeditiously and remains committed to global standards of quality and compliance,” it said. The site will continue to supply to the US markets all approved ANDAs and the inspection will help it receive pending ANDA approvals too, it further said. Shares of Marksans Pharma slumped 2.60 per cent at ₹26.20 on the NSE.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.